Astragaloside IV is a bioactive saponin first isolated from the dried plant roots of the genus Astragalus, which is used in traditional Chinese medicine1. It has diverse protective effects for the cardiovascular, immune, digestive, and nervous systems2.
One of the major sub-types of inflammatory bowel disease (IBD) is Ulcerative Colitis (UC). It is characterized by chronic, repeated intestinal disorders, such as diarrhea, mucilage or blood-pus stools. Nowadays, the pathogenesis of UC has not been clearly identified, but it is believed to have correlation with genetic susceptibility, immune imbalance, intestinal infection and alterations in commensally micro-biota3.
Intestinal barrier consists of epithelial layer, tight junctions and mucus layer. Amongst the pathogenic factors of Ulcerative Colitis, the distressed epithelial barrier function and augmented intestinal permeability have been considered as the prime factors in the development of colitis4.
It is well established that intrusions for mucosal remedial and epithelial barrier support could bound inflammation and prevent future injury5. Hence, strengthening epithelial resistance to harmful stimulus and improving intestinal fix could be effectual approaches for the healing of Ulcerative Colitis.
In this context, researchers conducted a study to investigate the therapeutic effect of astragaloside IV (AS-IV) on experimental colitis as well as its role in mucosal healing and barrier function6.
For this colitis was artificially induced to the rats (experimental animal). After that histological and colon tissue damage was checked. Mucosal barrier function was also evaluated. Immuno-histochemistry and RT-PCR assays were also performed.
After experiment authors observed that:
“We observed that the AS-IV decreased the Histological scores, myeloperoxidase activity and serum level of D-lactate and diamine oxidase, while mRNA expression of Muc-2 and Muc-3 were significantly increased. Moreover, the protein expression in the colon of colitis rats was significantly elevated, but the genes expression in colitis rats were markedly decreased, and these alteration were markedly reversed by AS-IV administration.”
It was then established that AS-IV attenuates colon inflammation in colitis rats via improving mucosal barrier function, the regulatory effect on the proliferation and differentiation of goblet cells may contribute to the therapeutic role of AS-IV in colitis.
Written by: Rabeeia
Your email address will not be published. Required fields are marked *
17 November, 2019